<DOC>
	<DOCNO>NCT02977299</DOCNO>
	<brief_summary>This multi-site , randomize , open-label , effectiveness trial compare three treatment arm Major Depressive Disorder ( MDD ) patient TRD currently ongoing , stable adequate antidepressant therapy ( ADT ) . Adequate ADT define therapeutically sufficient dose sufficient treatment period , would expect effective list MGH Antidepressant Treatment Response Questionnaire ( ATRQ ) . Patients randomize 1:1:1 fashion one three open-label treatment arm : ) aripiprazole augmentation , b ) rTMS augmentation , c ) switch venlafaxine XR .</brief_summary>
	<brief_title>Comparative Effectiveness Research Trial Antidepressant Incomplete Non-responders With Treatment Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1. woman men age 1880 , 2. MDD , least 12 week duration , accord Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criterion confirm Mini International Neuropsychiatric Interview ( MINI ; Sheehan et al , 1998 ) , 3. MontgomeryAsberg Depression Rating Scale ( MADRS Montgomery Asberg , 1979 ) score least 20 screen baseline assess site clinician , 4. meet criterion TRD current major depressive episode document MGH Antidepressant Treatment History Questionnaire ( ATRQ ) ( Chandler et al. , 2010 ) , define nonresponders ( less 50 % symptom improvement ) two depression treatment trial adequate dose duration define MGH ATRQ , 5. currently antidepressant adequate dose ( defined MGH ATRQ ) duration ( least 8 week ) , antidepressant dose stable past four week , document ( MGH ATRQ ) nonresponse ( le 50 % improvement ) current antidepressant . 6 . Patients pass MGH CTNI remote assessment , documentation provide site MGH CTNI . 1. pregnant breastfeed woman , woman childbearing potential use accepted mean birth control , woman positive urine pregnancy test , 2. patient receive treatment rTMS , aripiprazole , electroconvulsive therapy ( ECT ) , venlafaxine current episode , 3. patient express objection receive treatment least one three treatment arm study , 4. patient history bipolar disorder psychosis ( diagnosed MINI ) , 5. patient active alcohol substance abuse disorder within past 6 month ( diagnose MINI ) , 6. patient suicidal ideation degree , opinion evaluate clinician , participation study would place significantly increase risk suicide , 7. patient unstable medical issue degree , opinion evaluate clinician , participation study would place significant risk serious adverse event , patient screen hemoglobin A1c level great 7.5 % , patient epilepsy , dementia , Parkinson 's disease , Huntington 's Disease , 8. patient receive treatment vagus nerve stimulation ( VNS ) , 9. patient respond five FDAapproved antidepressant treatment trial adequate dose duration current episode , respond ECT previous episode 10. patient excluded medication , 11. patient positive urine screen drug test substance valid prescription valid medical reason , 12. patient currently abnormal thyroid function test , 13. patient receive least one dose monoamine oxidase inhibitor ( MAOI ) four week less prior , 14. patient concomitant psychotropic agent ( anticonvulsant , benzodiazepine , hypnotic , opiate , triiodothyronine ( T3 ) , modafinil , psychostimulants , buspirone , melatonin , omega3 fatty acid , folate , lmethylfolate , sadenosyl methionine , lithium ) dose least four week prior study entry agree continue dose acute phase study . 15 . Patients meet safety criterion TMS : history seizure , cardiac pacemaker , DBS VNS , brain aneurism clip metallic implant intracranial space . 16 . Also exclude individual receive administration ketamine current episode treatment depression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>